Targeted Therapies in Oncology

January 2021
Volume: 10
Issue: 1

December 2, 2020
Volume: 9
Issue: 18

December 1 2020
Volume: 9
Issue: 17

November 2 2020
Volume: 9
Issue: 16

November 1 2020
Volume: 9
Issue: 15

October 2 2020
Volume: 9
Issue: 14

October 1, 2020
Volume: 9
Issue: 13

September 1 2020
Volume: 9

August 1 2020
Volume: 9
Issue: 1

July 1 2020
Volume: 9
Issue: 9

July 2 2020
Volume: 9
Issue: 10

June 1 2020
Volume: 9
Issue: 8

May 1 2020
Volume: 9
Issue: 5

April 2 2020
Volume: 9
Issue: 6

April 1 2020
Volume: 9
Issue: 5

March 1 2020
Volume: 9
Issue: 4

February 2 2020
Volume: 9
Issue: 3

February 1 2020
Volume: 9
Issue: 2

January 2020
Volume: 9
Issue: 1
December 2
Volume: 8
Issue: 18

December 1
Volume: 8
Issue: 17

November 2 2019
Volume: 8
Issue: 16

November 1 2019
Volume: 8
Issue: 15

October 2 2019
Volume: 8
Issue: 14

October 2019
Volume: 8
Issue: 13

September 2019
Volume: 8
Issue: 12

August 2019
Volume: 8
Issue: 11

July 2019
Volume: 8
Issue: 9

July 2
Volume: 8
Issue: 10

June 2019
Volume: 8
Issue: 8
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
2
Real-World Data Show T-DXd Activity in HER2-Mutant NSCLC
3
FDA Panel Votes 10-3 In Favor of RP1 Plus Nivolumab for Advanced Melanoma
4
Durable Responses Seen With Cretostimogene in BCG-Unresponsive NMIBC
5
